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Abstract
Background: Melan-A and tyrosinase are new immunohistochemical markers that can be used in
the diagnosis of melanocytic lesions. The aim of this study was to investigate the correlation
between radiotherapy or clinicohistopathological parameters and the expression of melan-A and
tyrosinase in uveal melanoma.
Methods:  Thirty-six enucleated cases of uveal melanoma were studied. The formalin-fixed,
paraffin-embedded specimens were immunostained with monoclonal antibodies against melan-A
and tyrosinase. The samples were classified as either positive or negative. The chi-square or the
Student-t tests were used to test for the correlation of the expression rates of melan-A and
tyrosinase with clinico-pathological parameters.
Results: Melan-A and tyrosinase were positive in 33 (91.7%) and 35 (97.2%) of the specimens,
respectively. There was no significant association between the expression of melan-A or tyrosinase
and radiotherapy or any clinico-pathological parameter. All specimens were positive for at least one
of the immunohistochemical markers.
Conclusion: To the best of our knowledge this is the first study concluding that the expression
of melanocytic markers such as melan-A and tyrosinase is not influenced by radiotherapy or any
clinico-pathological parameter. Moreover, when tyrosinase and melan-A are used together, 100%
of the formalin-fixed, paraffin-embedded uveal melanoma samples tested positive for one of those
markers.
Background
Uveal melanoma is the most common primary intraocu-
lar malignancy in adults, with an incidence of 5–7 new
cases per million people per year.[1] Over the past few
decades, treatment of the primary tumor has drastically
improved and radiotherapy has replaced enucleation as
the preferred treatment of the primary tumor.[2] How-
ever, despite the growing success of treating the eye, the
systemic prognosis has not improved: the 5-year survival
rates have remained practically unchanged in recent dec-
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ades, ranging from 77 to 84% from 1973 to 1993, without
a statistically significant variation[2,3]. Tumor-related
death is mainly due to liver metastasis, which is usually
detected several years after the diagnosis and treatment of
the primary tumor[4].
The melan-A protein is a melanocytic differentiation anti-
gen, product of the MART-1 gene, and is thought to be
specific for melanocytic cells.[5] It was found to be a use-
ful addition to antibody panels for cutaneous melanocytic
lesions.[6] Tyrosinase is an enzyme involved in the initial
stages of melanin biosynthesis in melanocytes and
melanoma cells and, for that reason, is also considered a
biochemical marker of melanocytes.[7] A two-marker
polymerase chain reaction (PCR) using melan-A and tyro-
sinase has been described for the detection of Circulating
Malignant Cells (CMCs) in the peripheral blood of
patients with skin melanoma.[8] The combination of
these two markers was also described for the detection of
CMCs in uveal melanoma.[9,10] However, only a few
studies evaluated the co-expression of these immunohis-
tochemical markers in primary uveal melanomas.[11-14]
To the best of our knowledge, a study investigating the
influence of radiotherapy on the expression of markers of
melanocytic differentiation has never been done in uveal
melanoma.
The aim of this study was to investigate the expression of
melan-A and tyrosinase in uveal melanoma, and the cor-




Thirty-six patients with uveal melanoma were included in
the study based on the availability of representative tissue
and clinicopathological data. Subjects' pathological
reports and Cancer Registry entries were reviewed to pro-
vide the following information: age at diagnosis, gender,
previous ocular radiation therapy, largest tumor dimen-
sion (LTD), cell type, lymphocytic infiltration and pres-
ence of closed vascular loops.
The cell type was classified according to the modified Cal-
lender's classification of uveal melanoma [15]. Tumors
composed of only spindle cells were classified as spindle,
whereas tumors containing spindle and epithelioid cells
were classified as mixed. The LTD, in millimeters, was
measured by ultrasound prior to treatment. The classifica-
tion of lymphocytic infiltration and closed vascular loops
was done as described elsewhere. [16]
Tissue samples
Thirty-six enucleated eyes containing tumor tissue were
routinely fixed in 10% buffered formalin and subse-
quently paraffin-embedded. Paraffin blocks were
retrieved from the Henry C. Witelson Ocular Pathology
Laboratory and Registry, McGill University, Montreal,
Quebec, Canada.
Immunohistochemistry
Immunostaining was performed according to the avidin-
biotin complex technique. Briefly, 4 μm thick sections,
were deparaffinized in xylene and rehydrated through
graded ethanol washes. Endogenous peroxidase activity
was blocked with a 10-min wash with 3% hydrogen per-
oxide in methanol. Heat antigen retrieval was performed
with microwave treatment in citrate buffer (pH 6.0). Non-
specific binding was blocked with a 30-min wash with 1%
bovine serum albumin (BSA) in Tris-buffered saline (TBS,
pH 7.6).
Sections were incubated overnight with immunohisto-
chemistry-specific rabbit antibody for melan-A (NCL-L-
Melan-A, diluted 1: 25, Novocastra Laboratories Ltda,
United Kingdom) and tyrosinase (NCL-TYROS, diluted
1:25, Novocastra Laboratories Ltda, United Kingdom).
Following incubation with primary antibody at 4°C, sec-
tions were incubated with biotinylated goat anti-rabbit
secondary antibody (diluted 1:500; DAKO, Mississauga,
Ontario, Canada) for 30 min at room temperature. Sec-
tions were then incubated with horseradish peroxidase-
conjugated streptavidin-biotin complex (DAKO) for 30
min at room temperature. Immunostaining was visual-
ized using the 3-amino-9-ethylcarbazole (AEC) chro-
mogen (DAKO). Sections were counterstained with
hematoxylin and cover-slipped.
The omission of primary antibody and the use of non-
immune serum (0.1% BSA in TBS) served as a negative
control. Skin melanoma served as the positive control for
both antibodies.
Microscopic classification
Two independent ophthalmic pathologists analyzed the
slides by light microscopy and the final interpretation was
based on agreeing assessments. Samples were classified
into two categories: negative (if less than 10% of the
tumor cells displayed immunostaining) and positive (if
more than 10% of tumor cells displayed distinct immu-
nostaining, irrespective of the staining intensity). [12]
Statistical analysis
The chi-square test was used to test the correlation of
expression with gender, radiotherapy, cell type, lym-
phocytic infiltration and presence of vascular loops while
the student-T test was used for age and largest tumor
dimension. A P-value of less than 0.05 was considered to
be statistically significant.Journal of Carcinogenesis 2007, 6:6 http://www.carcinogenesis.com/content/6/1/6
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Data accumulation was acquired in accordance with




The sample studied was composed of 36 patients, 23
males (63.9%) and 13 females (36.1%). Age at diagnosis
was 65 ± 11 years (mean ± standard deviation). Twenty-
one patients were treated with primary enucleation while
15 were treated with radiotherapy and enucleation. The
time period between radiotherapy and enucleation was
52.4 ± 44.1 months (mean ± standard deviation). Regard-
ing cell type, 3 were classified as spindle and 33 as mixed
cell type uveal melanomas. LTD was 15 ± 4.9 mm (mean
± standard deviation). Lymphocytic infiltration and
closed vascular loops were present in 8 (22.2%) and 10
(27.8%) patients, respectively.
Expression of melan-A and tyrosinase
Immunoexpression of melan-A and tyrosinase was cyto-
plasmatic (Fig. 1). The staining pattern was diffuse in the
positive samples for both markers. Melan-A and tyrosi-
nase were positive in 33 (91.7%) and 35 (97.2%) of the
specimens, respectively.
All specimens were positive for at least one of the immu-
nohistochemical markers.
Correlation with clinicopathological parameters
There was no observable association between the expres-
sion of each melanocytic marker and gender, radiother-
apy, cell type, lymphocytic infiltration and presence of
closed vascular loops (p > 0.05). Age and LTD were not
correlated with the expression of melan-A either. The sta-
tistical analysis for age and LTD could not be performed
for tyrosinase given the small number of negative results
(Tables 1 and 2).
Non-neoplastic ocular tissues
Melan-A stained normal uveal melanocytes in a variable
fashion. A similar pattern was noted with tyrosinase stain-
ing, albeit with less intensity. No immunostaining of any
other ocular structure was seen with either marker.
Discussion
HMB-45 and S-100 are the two most common markers
used for the diagnosis of uveal melanoma.[17] HMB-45
recognizes the protein gp100[18] and is more specific
than S-100, which is positive in other non-melanocytic
tumors[19]. Melan-A and tyrosinase were recently
described as markers of melanocytic differentiation. Stud-
ies with formalin-fixed, paraffin-embedded sections of
cutaneous melanoma showed positive results for melan-A
and tyrosinase in 97% and 90% of the cases, respectively
[20].
De Vries et al[14] studied the expression of melan-A and
tyrosinase in cryostat sections of 32 cases of uveal
melanoma and all of them were positive. Four specimens
of uveal metastatic lesions also stained positive for both
markers. However, it was uncertain whether the same pos-
itive results could be achieved in formalin-fixed, paraffin-
embedded specimens. In addition, clinical data of the
patients, including method of treatment, was not availa-
ble.
Posteriorly, formalin-fixed, paraffin-embedded sections
of uveal melanoma were studied for the expression of
melan-A and tyrosinase [11-13]. High rates of positive
results were seen for both markers and the staining was
not influenced by cell type. However, as in the previous
study, no clinical information regarding any treatment
prior to enucleation was provided.
Ionizing radiation is known to induce a myriad of patho-
logical changes in different tissues [21]. At a molecular
level, exposure of cells to ionizing radiation results in
immediate and widespread oxidative damage. Following
these immediate biochemical events, a wide range of cov-
alent damage is induced in cellular DNA, including strand
breaks, base and sugar damage, cross-links between DNA
strands and DNA-protein bonds. This DNA damage leads
to cell cycle arrest and/or apoptosis [22]. Although in vitro
studies have shown that radiation causes chromatid and
isochromatid chromosome breaks in melanoma cells.
[23], uveal melanoma is notoriously highly radioresistant
[24].
An analysis of melanoma cell type, before and after radio-
therapy, was performed by Char et al [25] in patients that
had a preradiation fine needle aspiration biopsy (FNAB)
and later required an enucleation. In a group of 35 uveal
melanoma patients, 20 had no sequential change in the
cell type, 14 had increased malignancy based on sequen-
tial studies, and 1 specimen showed a change from a
mixed to a predominantly spindle B cell type. The expres-
sion of melanocytic markers was not investigated.
To the best of our knowledge this is the largest sample of
formallin-fixed, paraffin-embedded specimens of uveal
melanoma, studied for the co-expression of melan-A and
tyrosinase. Moreover, this is the first time that the expres-
sion of those markers was correlated with clinico-his-
topathological parameters other than cell type. We
showed that all samples were positive for at least one of
the markers, regardless of any tumor characteristic or pre-
vious treatment with radiation.Journal of Carcinogenesis 2007, 6:6 http://www.carcinogenesis.com/content/6/1/6
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Photomicrographies Figure 1
Photomicrographies. Choroidal melanoma showing positive immunostaining for melan-A (A) and negative for tyrosinase (B) 
Another patient now showing negative immunostaining for melan-A (C) and positive for tyrosinase (D). Choroidal melanoma 
enucleated after failure of treatment with brachytherapy. Positive Immunostaining for melan-A (E) and tyrosinase (F). (red 
chromogen, ×400).Journal of Carcinogenesis 2007, 6:6 http://www.carcinogenesis.com/content/6/1/6
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The conclusions of our study bring two important impli-
cations. First, the association of these two markers is use-
ful to confirm the diagnosis in atypical cases of uveal
melamoma, because in every sample at least one of them
will be positive. The second implication is related to the
detection of CMCs using RT-PCR for melan-A and tyrosi-
nase. It is important to note that the primary tumor con-
sistently expresses those markers independent of any
tumor feature and even in patients that were treated con-
servatively with radiation. Consequently, our results sug-
gest that the use if both aformentioned markers together
will ensure that CMCs, if present, will not avoid detection.
Given the overall high expression of both markers and the
small number of negative results, a statistical analysis con-
cerning the timing of radiotherapy before enucleation
could not be performed. However, our sample was com-
posed of patients that received radiotherapy as soon as
one month prior to the surgery and others that were enu-
cleated almost ten years after. Although a higher number
of uveal melanoma specimens should be studied first, we
believe that it is unlikely that the time of radiotherapy
plays any role in the expression of the melanocytic mark-
ers herein studied.
In agreement with previous studies, our results support
the evidence that an immunohistochemical panel con-
taining these two markers is highly effective in the diagno-
sis of uveal melanoma.
Table 2: Correlation of the expression of tyrosinase with clinico-pathological parameters
Positive (35) Negative (1) Test p-value
Age at diagnosis (years, mean ± standard deviation) 65 ± 11.2 67 n/a n/a
Sex (n)
Male 22 1 chi-square 0.45
Female 13 0
Radiotherapy (n)
yes 15 0 chi-square 0.39
no 20 1
Cell type (n)
Spindle 3 32 chi-square 0.76
Mixed 01
Largest tumor dimesion (mm, mean ± standard deviation) 15 ± 4.9 8.5 n/a n/a
lymphocytic infiltration (n)
present 8 27 chi-square 0.59
absent 01
Closed vascular loops (n)
present 10 25 chi-square 0.53
absent 0
Table 1: Correlation of the expression of melan-A with clinico-pathological parameters
Positive (33) Negative (3) Test p-value
Age at diagnosis (years, mean ± standard deviation) 65 ± 10.8 60 ± 14.4 Student-t 0.43
Sex (n)
Male 21 2 chi-square 0.92
Female 12 1
Radiotherapy (n)
yes 14 1 chi-square 0.76
no 19 2
Cell type (n)
Spindle 3 0 chi-square 0.59
Mixed 30 3
Largest tumor dimesion (mm, mean ± standard deviation) 14.8 ± 5.1 12 ± 2.8 Student-t 0.46
Lymphocytic infiltration (n)
present 8 0 chi-square 0.33
absent 25 3
Closed vascular loops (n)
present 10 0 chi-square 0.26
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